http://www.unboundmedicine.com/medline/ebm/research/paclitaxelUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.http://www.unboundmedicine.com/medline/ebm/record/19894274/full_citation/Self_emulsifying_O/W_formulations_of_paclitaxel_prepared_from_mixed_nonionic_surfactants_Lo JT, Chen BH, Lee TM, et al. 
Self-emulsifying O/W formulations of paclitaxel prepared from mixed nonionic surfactants. [JOURNAL ARTICLE]
J Pharm Sci 2009 Nov 5.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19892746/full_citation/Phase_I_dose_finding_study_of_paclitaxel_with_panitumumab_carboplatin_and_intensity_modulated_radiotherapy_in_patients_with_locally_advanced_squamous_cell_cancer_of_the_head_and_neck_Wirth LJ, Allen AM, Posner MR, et al. 
Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. [JOURNAL ARTICLE]
Ann Oncol 2009 Nov 5.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19892052/full_citation/Comparison_of_the_efficacy_and_safety_of_zotarolimus__sirolimus__and_paclitaxel_eluting_stents_in_patients_with_ST_elevation_myocardial_infarction_Lee CW, Park DW, Lee SH, et al. 
Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. [Journal Article, Research Support, Non-U.S. Gov't]
Am J Cardiol 2009 Nov 15; 104(10):1370-6.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19892051/full_citation/Clinical_outcomes_after_sirolimus_eluting_paclitaxel_eluting_and_bare_metal_stents__from_the_first_phase_of_the_prospective_multicenter_German_DES_DE_Registry__Nienaber CA, Akin I, Schneider S, et al. 
Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry). [Journal Article]
Am J Cardiol 2009 Nov 15; 104(10):1362-9.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19891433/full_citation/Evaluating_Transition_Metal_Catalyzed_Transformations_for_the_Synthesis_of_Laulimalide_Trost BM, Amans D, Seganish WM, et al. 
Evaluating Transition-Metal-Catalyzed Transformations for the Synthesis of Laulimalide. [JOURNAL ARTICLE]
J Am Chem Soc 2009 Nov 5.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19889612/full_citation/A_phase_I_open_label_dose_escalation_study_of_oral_BIBF_1120_combined_with_standard_paclitaxel_and_carboplatin_in_patients_with_advanced_gynecological_malignancies_du Bois A, Huober J, Stopfer P, et al. 
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. [JOURNAL ARTICLE]
Ann Oncol 2009 Nov 4.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19887966/full_citation/Phase_II_Trial_of_Nanoparticle_Albumin_Bound_Paclitaxel_Carboplatin_and_Bevacizumab_in_First_line_Patients_with_Advanced_Nonsquamous_Non_small_Cell_Lung_Cancer_Reynolds C, Barrera D, Jotte R, et al. 
Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer. [JOURNAL ARTICLE]
J Thorac Oncol 2009 Oct 31.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19887548/full_citation/CYT997:_a_novel_orally_active_tubulin_polymerization_inhibitor_with_potent_cytotoxic_and_vascular_disrupting_activity_in_vitro_and_in_vivo_Burns CJ, Fantino E, Phillips ID, et al. 
CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo. [JOURNAL ARTICLE]
Mol Cancer Ther 2009 Nov 3.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19887543/full_citation/A_phase_I_trial_of_paclitaxel_and_trastuzumab_in_combination_with_interleukin_12_in_patients_with_HER2/neu_expressing_malignancies_Bekaii-Saab TS, Roda JM, Guenterberg KD, et al. 
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. [JOURNAL ARTICLE]
Mol Cancer Ther 2009 Nov 3.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19887304/full_citation/Association_of_pegylated_liposomal_doxorubicin_and_ifosfamide_in_early_recurrent_ovarian_cancer_patients:_A_Multicenter_Phase_II_Trial_Joly F, Sevin E, Lortholary A, et al. 
Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: A Multicenter Phase II Trial. [JOURNAL ARTICLE]
Gynecol Oncol 2009 Nov 2.
Abstract | Full Citation